Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP0057 + olaparib
- Development stage
- Unknown
- Lead developer
- Ellipses Pharma
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
EP0057 + olaparib is an investigational drug combination for cancer therapy. **EP0057** is a nanoparticle-drug conjugate consisting of a cyclodextrin-linked camptothecin, facilitating improved delivery and accumulation of the cytotoxic camptothecin in tumor tissue[3]. **Olaparib** is a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes (PARP1 and PARP2); inhibition of these enzymes blocks DNA repair mechanisms, particularly in tumor cells with BRCA mutations, promoting cell death[2][4]. The combination aims to enhance antitumor activity: EP0057 induces DNA damage, and olaparib inhibits DNA repair, leading to synthetic lethality. This combination is being developed primarily for small cell lung cancer and advanced ovarian cancer[1][3][5][7].
- Brand names
- Lynparza
- Other names
- camptothecin nanoparticle drug conjugate + olaparibEP0057 + Lynparza
02
Targets
TOP1 (DNA Topoisomerase I)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on EP0057 + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP0057 + olaparib.